Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
49 hedge funds and large institutions have $25.4M invested in Catalyst Pharmaceutical in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 18 reducing their positions, and 15 closing their positions.
2.49% less ownership
Funds ownership: 30.64% → 28.15% (-2.5%)
21% less funds holding
Funds holding: 62 → 49 (-13)
67% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 18
83% less capital inflows, than outflows
Capital inflows: $327K | Capital outflows: $1.93M
87% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSA Capital Partners
London,
United Kingdom
|
+$113K |
| 2 |
Corrado Advisors
Ramsey,
New Jersey
|
+$70.8K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$63.9K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$33.5K |
| 5 |
BlackRock Fund Advisors
San Francisco,
California
|
+$29.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$298K |
| 2 |
Credit Suisse
Zurich,
Switzerland
|
-$253K |
| 3 |
Paloma Partners
Greenwich,
Connecticut
|
-$200K |
| 4 |
DRW Securities
Chicago,
Illinois
|
-$168K |
| 5 |
Millennium Management
New York
|
-$153K |
CPRX Hedge Fund Activity: Q3 2016 in Review
49 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2016, worth a combined $25.4M — up 41% from $18M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CPRX and 2 opened new positions — a net loss of 13 holders — while 18 trimmed existing stakes and 6 added.
The largest buyer was GSA Capital Partners, adding an estimated $113K. The largest seller was Deutsche Bank, cutting an estimated $298K.
- 49 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2016, down from 62 in Q2 2016.
- Funds reported $25.4M of Catalyst Pharmaceutical stock for Q3 2016, up 41% quarter-over-quarter.
- 2 funds opened new Catalyst Pharmaceutical positions in Q3 2016 and 15 closed out, a net change of -13 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2016 was GSA Capital Partners, an estimated $113K added.
- The largest Catalyst Pharmaceutical seller in Q3 2016 was Deutsche Bank, an estimated $298K sold.
Based on aggregated 13F filings for Q3 2016.